Firma Immunic, Autor bei Presse-Blog

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

17. November 202013. Dezember 2023 Firma ImmunicFirmeninternanatomic, clinical, colitis, fiscal, immunic, immunic's, imu, lupus, market, patients, revenue, securities, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of a Scientific-Medical Advisory Board (SAB). Inaugural members include Drs. Fred D. Lublin, Mehr

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

6. November 202013. Dezember 2023 Firma ImmunicFinanzen / Bilanzencalvid, dosing, immunic, immunic's, imu, market, patients, revenue, rrms, statements, syndrome, uhcw, unblinded, vtl, with

– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 – – 200 Patients Randomized in Phase 2 Trial of Mehr

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

2. November 202013. Dezember 2023 Firma ImmunicForschung und Entwicklungcalvid, cell, cells, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and randomized 200 patients, pre-specified in the protocol as sufficient to Mehr

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

20. Oktober 202013. Dezember 2023 Firma ImmunicForschung und Entwicklungcalvid, fiscal, hepatitis, immunic, immunic's, imu, innovfin, market, patients, revenue, statements, syndrome, ulcerative, vaccines, with

European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19 IMU-838 is an orally available small molecule, which, because of its broad-spectrum antiviral effect Mehr

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

28. September 202013. Dezember 2023 Firma ImmunicForschung und Entwicklungcalvid, dynamics, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, unblinded, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase Mehr

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

11. September 202013. Dezember 2023 Firma ImmunicForschung und Entwicklung45mg, brain, dosing, immunic, immunic's, imu, market, neutropenia, patients, revenue, rrms, statements, syndrome, vidofludimus, with

Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations T ime Course of MRI Lesion Suppression Shows Reduction of Lesions Already Present at First Post-Baseline Scan at Week 6, Validating Rapid Attainment of Stable Therapeutic Drug Mehr

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

20. August 202013. Dezember 2023 Firma ImmunicGesundheit & Medizincolitis, expenses, fiscal, hella, ibs, immunic, imu, liability, patients, revenue, sec, securities, statements, sugar, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-856, Mehr

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters‘ Option to Purchase Additional Shares

10. August 2020 Firma ImmunicFinanzen / Bilanzenclinical, expenses, financial, fiscal, immunic, immunic's, imu, jurisdiction, prospectus, report, revenue, securities, statements, svb, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 5,750,000 shares of its common stock at Mehr

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

5. August 2020 Firma ImmunicFinanzen / Bilanzenclinical, expenses, financial, fiscal, immunic, immunic's, imu, jurisdiction, prospectus, report, revenue, securities, statements, svb, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock Mehr

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

4. August 202013. Dezember 2023 Firma ImmunicFinanzen / Bilanzenclinical, financial, fiscal, immunic, immunic's, jurisdiction, market, prospectus, report, revenue, sandler, securities, statements, svb, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell 5 million shares of its common stock Mehr

Autor: Firma Immunic